MA32389B1 - Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue - Google Patents

Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue

Info

Publication number
MA32389B1
MA32389B1 MA33418A MA33418A MA32389B1 MA 32389 B1 MA32389 B1 MA 32389B1 MA 33418 A MA33418 A MA 33418A MA 33418 A MA33418 A MA 33418A MA 32389 B1 MA32389 B1 MA 32389B1
Authority
MA
Morocco
Prior art keywords
heart failure
acute heart
dyspnea associated
treat dyspnea
treat
Prior art date
Application number
MA33418A
Other languages
Arabic (ar)
English (en)
Inventor
Elaine Unemori
Sam L Teichman
Gad Cotter
Dennis R Stewart
Martha Jo Whitehouse
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of MA32389B1 publication Critical patent/MA32389B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes permettant de réduire une décompensation par une intervention à chaud, notamment chez des sujets atteints d'une défaillance cardiaque aiguë décompensée. En particulier, ces méthodes permettent de traiter une décompensation cardiaque aiguë par l'administration d'une dose efficace au plan pharmaceutique de relaxine.
MA33418A 2008-05-16 2010-12-10 Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue MA32389B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27
PCT/US2009/044249 WO2009140659A2 (fr) 2008-05-16 2009-05-15 Méthode de traitement de la dyspnée associée à une insuffisance cardiaque aiguë

Publications (1)

Publication Number Publication Date
MA32389B1 true MA32389B1 (fr) 2011-06-01

Family

ID=40834101

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33418A MA32389B1 (fr) 2008-05-16 2010-12-10 Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue

Country Status (30)

Country Link
US (7) US8053411B2 (fr)
EP (2) EP2288373B1 (fr)
JP (4) JP5651586B2 (fr)
CN (3) CN103212063B (fr)
AR (1) AR071810A1 (fr)
AU (1) AU2009246114B2 (fr)
BR (1) BRPI0913011A2 (fr)
CA (1) CA2724540C (fr)
CR (1) CR11749A (fr)
CY (1) CY1116925T1 (fr)
DK (1) DK2288373T3 (fr)
EA (2) EA022948B1 (fr)
ES (1) ES2546287T3 (fr)
GB (2) GB2462221B (fr)
HK (1) HK1202054A1 (fr)
HR (1) HRP20150845T1 (fr)
HU (1) HUE025483T2 (fr)
IL (3) IL208992A (fr)
MA (1) MA32389B1 (fr)
MX (1) MX2010012450A (fr)
MY (2) MY159803A (fr)
NZ (3) NZ701038A (fr)
PL (1) PL2288373T3 (fr)
PT (1) PT2288373E (fr)
SG (2) SG191587A1 (fr)
SI (1) SI2288373T1 (fr)
TW (1) TWI386202B (fr)
UA (1) UA99953C2 (fr)
WO (1) WO2009140659A2 (fr)
ZA (1) ZA201007449B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140659A2 (fr) * 2008-05-16 2009-11-19 Corthera, Inc. Méthode de traitement de la dyspnée associée à une insuffisance cardiaque aiguë
MX336145B (es) * 2008-05-16 2016-01-08 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
US20130053318A1 (en) 2010-03-10 2013-02-28 Parry Laura Modulating aquaporins with relaxin
EP2601532B1 (fr) * 2010-08-06 2016-01-27 Mycartis N.V. Utilisation de perlecan en tant que biomarqueur d'un dysfonctionnement rénal
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
US9382305B2 (en) * 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2013059879A1 (fr) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions et procédés destinés au traitement de la fibrose et de maladies fibrogènes
PT2814513T (pt) * 2012-02-14 2018-03-02 Univ California Entrega sistémica e expressão regulada de genes parácrinos para doenças cardiovasculares e outras doenças
ES2929283T3 (es) 2012-05-04 2022-11-28 Us Health Moduladores del receptor de relaxina 1
EA030354B1 (ru) * 2012-10-26 2018-07-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ уменьшения диспноэ у пациента с острой сердечной недостаточностью
US9884039B2 (en) 2013-04-05 2018-02-06 Scpharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
SG11201605273XA (en) * 2014-02-03 2016-08-30 Novartis Ag Filters for infusion sets
EP2946788A1 (fr) * 2014-05-23 2015-11-25 Immundiagnostik AG Procédé et composition pour le traitement de l'insuffisance cardiaque avec la fraction d'éjection préservée
BR112016028833A2 (pt) * 2014-06-13 2017-08-22 Novartis Ag uso de serelaxinaa para reduzir gdf-15
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
WO2017139164A1 (fr) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systèmes et procédés de surveillance d'un patient
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
US12403120B2 (en) 2018-12-10 2025-09-02 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
EP3906019B1 (fr) 2019-01-04 2025-11-26 SQ Innovation AG Compositions pharmaceutiques de furosémide
EP3906020B1 (fr) 2019-01-04 2025-12-31 SQ Innovation AG Compositions pharmaceutiques de torsémide et leurs utilisations
CA3128033A1 (fr) 2019-01-31 2020-08-06 Scpharmaceuticals Inc. Formulations pharmaceutiques liquides concentrees de furosemide et leurs methodes d'administration
AU2023332056A1 (en) 2022-08-31 2025-03-13 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment
WO2025056188A1 (fr) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Médicament de relaxine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
EP0707650B1 (fr) * 1993-06-21 2003-05-21 Genentech, Inc. Procede de production de relaxine humaine
WO1995003822A2 (fr) * 1993-07-27 1995-02-09 Mario Bigazzi Emploi de la relaxine a titre therapeutique ou preventif
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
DE69624925T2 (de) 1995-08-15 2003-09-04 Connetics Corp., Palo Alto Verwendung von relaxin zur stimulierung der angiogenese
DE60128540T2 (de) 2000-02-09 2008-01-31 Bas Medical, Inc., San Mateo Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
WO2006075819A1 (fr) * 2004-03-30 2006-07-20 Industry-Academic Cooperation Foundation, Yonsei University Systeme de delivrance de gene contenant le gene de la relaxine et composition pharmaceutique utilisant la relaxine
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US20080077025A1 (en) * 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
AU2008273813B2 (en) 2007-07-12 2013-06-13 Compugen Ltd. Bioactive peptides and method of using same
MX336145B (es) 2008-05-16 2016-01-08 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
WO2009140659A2 (fr) * 2008-05-16 2009-11-19 Corthera, Inc. Méthode de traitement de la dyspnée associée à une insuffisance cardiaque aiguë

Also Published As

Publication number Publication date
US20150320834A1 (en) 2015-11-12
NZ701038A (en) 2016-01-29
DK2288373T3 (en) 2015-09-28
TW200948353A (en) 2009-12-01
HK1139051A1 (en) 2010-09-10
MX2010012450A (es) 2011-03-21
HK1187550A1 (zh) 2014-04-11
PT2288373E (pt) 2015-10-19
US9205132B2 (en) 2015-12-08
US8053411B2 (en) 2011-11-08
US20130210730A1 (en) 2013-08-15
IL208992A (en) 2013-09-30
EP2829280A1 (fr) 2015-01-28
JP2011520918A (ja) 2011-07-21
CN106177914A (zh) 2016-12-07
CN103212063B (zh) 2015-07-22
WO2009140659A3 (fr) 2010-07-22
HUE025483T2 (en) 2016-02-29
GB2459983B (en) 2010-04-28
US20120040902A1 (en) 2012-02-16
HRP20150845T1 (hr) 2015-11-06
US20130116181A1 (en) 2013-05-09
IL228244A (en) 2016-10-31
CY1116925T1 (el) 2017-04-05
US9579363B2 (en) 2017-02-28
US9066916B2 (en) 2015-06-30
HK1202054A1 (en) 2015-09-18
IL247351A0 (en) 2016-09-29
UA99953C2 (uk) 2012-10-25
CA2724540C (fr) 2014-07-08
JP2016053040A (ja) 2016-04-14
MY158327A (en) 2016-09-30
CA2724540A1 (fr) 2009-11-19
AU2009246114B2 (en) 2013-01-31
EA022948B1 (ru) 2016-03-31
BRPI0913011A2 (pt) 2019-09-03
WO2009140659A2 (fr) 2009-11-19
TWI386202B (zh) 2013-02-21
PL2288373T3 (pl) 2015-11-30
AR071810A1 (es) 2010-07-14
GB0918132D0 (en) 2009-12-02
EP2288373A2 (fr) 2011-03-02
NZ598709A (en) 2013-09-27
GB2459983A (en) 2009-11-18
JP2013040174A (ja) 2013-02-28
CR11749A (es) 2011-02-11
AU2009246114A1 (en) 2009-11-19
HK1151229A1 (en) 2012-01-27
IL208992A0 (en) 2011-01-31
GB2462221A (en) 2010-02-03
US8415301B2 (en) 2013-04-09
SG10201609580YA (en) 2016-12-29
US20120040903A1 (en) 2012-02-16
US20170151311A1 (en) 2017-06-01
JP5638044B2 (ja) 2014-12-10
GB0908432D0 (en) 2009-06-24
US8372809B2 (en) 2013-02-12
GB2462221B (en) 2010-09-01
EP2288373B1 (fr) 2015-06-24
JP5651586B2 (ja) 2015-01-14
SG191587A1 (en) 2013-07-31
CN103212063A (zh) 2013-07-24
EA201500552A1 (ru) 2016-07-29
ES2546287T3 (es) 2015-09-22
JP2015013870A (ja) 2015-01-22
EA201001771A1 (ru) 2011-06-30
US20100048475A1 (en) 2010-02-25
NZ589009A (en) 2012-05-25
HK1140693A1 (en) 2010-10-22
SI2288373T1 (sl) 2015-12-31
MY159803A (en) 2017-02-15
CN102036679A (zh) 2011-04-27
ZA201007449B (en) 2011-06-29
JP5875646B2 (ja) 2016-03-02

Similar Documents

Publication Publication Date Title
EA201001771A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
EP2294184A4 (fr) Traitement de maladies oculaires et d une néovascularisation excessive utilisant un traitement combiné
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
JP2012046524A5 (fr)
EA201200977A1 (ru) Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами
MX389927B (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
EA201101568A1 (ru) Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
MX2013012284A (es) Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
EA201170425A1 (ru) Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
MX367811B (es) D-metadona para el tratamiento de síntomas psiquiátricos.
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
EA201190140A1 (ru) Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор
MX2011012310A (es) Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen).
EA201690327A1 (ru) Терапевтические способы
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
TR201900665T4 (tr) Diyabetik nefropatinin tedavi yöntemi.
EA201491048A1 (ru) Соединения двухцепочечных рнк к casp2 и их применение
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы